Introduction
============

"Pulmonary arterial hypertension" (PAH) is a common cardiovascular complication in thalassemic patients. It is a progressive disease that causes exercise limitation, right ventricular failure, and death. One study found that almost 60% of cases in a large cohort of 110 thalassemia intermedia (TI) patients had developed PAH.[@b1-ijgm-7-411] Its prevalence in Thailand has been found to be 43%.[@b2-ijgm-7-411] Another study has reported thrombi in small pulmonary arteries in 44% of hemoglobin E/β thalassemia (E/β-Thal) autopsies.[@b3-ijgm-7-411] PAH is due to increased pulmonary vascular resistance.[@b1-ijgm-7-411] In thalassemia, PAH could be due to an increased pulmonary blood flow from chronic anemia, and the oxidative stress resulting from chronic hemolysis is enhanced by iron overload. The possible mechanisms leading to PAH in thalassemia may involve platelet activation and the coagulation cascade.[@b4-ijgm-7-411]--[@b10-ijgm-7-411] Therapeutic strategies for dealing with PAH in thalassemia are controversial. Some authors have suggested that the PAH development can be prevented by starting transfusion and chelation therapy early in life for patients with TI.[@b1-ijgm-7-411],[@b11-ijgm-7-411]

In the study reported here, we compared pulmonary artery systolic pressure (PASP) and 6-minute walk distance after 1 year of follow-up in E/β-Thal with PAH patients who received chronic blood transfusions versus those who received occasional transfusions.

Materials and methods
=====================

A nonrandomized clinical trial was conducted at the Hematological Outpatient Clinic at Chiang Rai Hospital, Thailand. All adult (≥15 years) cases of E/β-Thal with PAH (defined as PASP \>35 mmHg by Doppler echocardiography) attending the clinic between June 2011 and November 2012 were evaluated and followed for the next 12 months. Inclusion criteria consisted of TI and serum ferritin level \<2,500 μg/dL in patients capable of being followed-up who signed informed consent to participate in the study. Exclusion criteria were patients who had clinical evidence of other secondary causes of PAH, including human immunodeficiency virus infection, collagen vascular diseases, cirrhosis, and chronic obstructive airway diseases, acquired heart disease associated with pulmonary venous hypertension; mitral valve disease; congenital heart disease; and hyperthyroidism.

After the physician advised patients that they may gain some benefit from chronic blood transfusions; patients were classified into one of two groups according to their preference. Group 1 patients were those with a preference for chronic blood transfusions. Patients in this group would receive one to two units of leukocyte-poor packed red cells every 2--4 weeks to maintain the pre-transfusion hemoglobin level of ≥7.0 g/dL over 1 year. Group 2 patients, comprising those patients who indicated a preference for occasional blood transfusions, would receive occasional transfusions not more often than every 4 weeks. All patients were treated with medications following standard guidelines, including intensive chelation therapy when their serum ferritin level was above 1,000 μg/dL.

Project exclusion rule
----------------------

The patients who developed an alloantibody to red blood cells and for whom the blood bank could not regularly supply compatible blood and/or who had serious blood transfusion complications such as anaphylaxis, acute pulmonary edema, or a serum ferritin level \>2,500 μg/dL (serum ferritin monitoring was undertaken every 3 months) were excluded from the trial and were managed by the hospital's standard guidelines.

Blood transfusion
-----------------

All transfusions were undertaken following the standard operating procedures of our blood bank, which adhere to the Thai Red Cross Society's National Blood Center.[@b12-ijgm-7-411] To prevent alloimmunization, transfusions were of blood phenotypically matched for Rhesus (Rh) and other alloantibodies, with leukocyte-poor (depleted) packed red cells at 250--350 cc/unit, and the standard complication monitoring system for blood transfusions was observed.

Indicators
----------

PASP and 6-minute walk distance[@b13-ijgm-7-411] were measured at baseline and at 6 and 12 months. The clinical outcomes consisted of functional class status, clinical right heart failure, and oxygen saturation. Functional class status was defined by the New York Heart Association (NYHA) Functional Classification[@b14-ijgm-7-411] (I: no symptoms with ordinary physical activity; II: symptoms with ordinary activity and slight limitation of activity; III: symptoms with less than ordinary activity, marked limitation of activity; IV: symptoms with any activity or even at rest). Echocardiography was performed by the same cardiologist. The patients' history, including blood transfusion frequency and splenectomy status, was blinded during echocardiographic examinations.

The study protocol was approved by the Institutional Research Ethics Committee, Faculty of Medicine, Chiang Mai University and Chiang Rai Hospital.

Study size estimation
---------------------

The sample size was estimated from a pilot study comparing the mean PASP difference between two independent groups. A mean PASP of the patients was recorded before and after treatments for 1 year. The calculation was based on a type I error at 0.05 and type II error at 0.1. When using a standard statistical package to calculate the number of samples needed with the ratio of the patients of the two groups being 1:1, six subjects per treatment group were required. We aimed to collect the data from at least 14 patients per treatment group.

Echocardiographic procedure
---------------------------

Complete two-dimensional, M-mode, and Doppler (pulsed wave, continuous wave, and color) echocardiography was performed at rest. In the study patients, a tricuspid regurgitation jet was sought from all available mid-precordial and apical positions until a flow signal with the maximum spectral representation of the highest velocities was obtained. Peak velocity was recorded from a holosystolic regurgitant jet. From the maximum velocity (V) of the regurgitant jet, the systolic pressure gradient (ΔP) between the right ventricle and the right atrium was calculated by the modified Bernoulli equation (ΔP =4V[@b2-ijgm-7-411]).[@b15-ijgm-7-411] Right atrial pressure was estimated by the response of the inferior vena cava diameter to inspiration. Right atrial pressure was assumed to be 5 mmHg if the inferior vena cava completely collapsed with inspiration, 10 mmHg if the inferior vena cava diameter decreased more than 50% during inspiration, and 15 mmHg if it decreased less than 50%. If the inferior vena cava diameter was larger than 2.5 cm and reduced by less than 50% during inspiration, right atrial pressure was assumed to be 20 mmHg.[@b16-ijgm-7-411] Adding the transtricuspid gradient to the mean right atrial pressure provided the right ventricular systolic pressure or peak systolic pulmonary arterial pressure in the absence of right ventricular outflow tract obstruction. PAH was defined as a PASP \>35 mmHg.[@b17-ijgm-7-411] In cases with an absence of tricuspid regurgitation, the end of the diastolic pulmonic regurgitant flow velocity was calculated using the pressure gradient between the pulmonary artery and right ventricular end diastolic pressure. Pulmonary artery pressure =4 (VPR)[@b2-ijgm-7-411] + right atrial pressure.

Statistical analysis
--------------------

The baseline characteristics were compared using exact probability tests for categorical variables; Student's *t*-test or Wilcoxon rank-sum test was used to compare the mean difference of continuous variables. Propensity score adjustment was used to control confounding by chronic blood transfusion indication and contraindication. Propensity scores for receiving chronic blood transfusions versus occasional transfusions were calculated from a logistic regression model that estimated the likelihood of receiving chronic blood transfusions based on the observed patient characteristics. Gaussian and an exponential risk regression were carried out. Uni-variable and multivariable regression analyses were used to evaluate the effects of chronic blood transfusions. Data are presented by frequency, percentage, mean, median, standard deviation (SD), range, beta coefficient, 95% confidence interval, and *P*-value. All statistical analyses were two-tailed. A *P*-value of \<0.05 was considered statistically significant.

Results
=======

A total of 30 patients with E/β-Thal were enrolled in the study, 16 (53.3%) in the chronic blood transfusion group (Group 1) and 14 (46.7%) in the occasional transfusion group (Group 2). The mean age of the patients was 36.1±14.6 and 34.1±15.2 years. Patients' mean PASP was 59.7±15.1 and 49.0±13.8 mmHg, while eight (50.0%) and four (28.6%) patients were post-splenectomy in Group 1 and Group 2, respectively. The baseline characteristics of the patients did not differ significantly between the two groups, except in terms of NYHA classification and PAH severity ([Table 1](#t1-ijgm-7-411){ref-type="table"}). More patients in Group 1 had a functional NYHA class of III than those in Group 2 (5 \[31.3%\] vs 0 \[%\] patients, *P*=0.045) and PAH severity was greater in Group 1 than in Group 2 (mild: 4 \[25.0%\] vs 10 \[71.4%\] patients, *P*=0.049; moderate: 8 \[50.0%\] vs 2 \[14.3%\]; severe: 4 \[25.0%\] vs 2 \[14.3%\]).

During the follow-up period, the mean PASP was 50.4±14.6 versus 49.4±16.9 at 6 months and 48.8±18.8 versus 54.1±21.4 mmHg at 12 months, in Groups 1 and 2, respectively. At 6 months, mean 6-minute walk distance was 388.7±59.2 versus 368.6±61.1 m, and 403.7±53.8 versus 350.0±82.9 m at 12 months in Group 1 and Group 2, respectively, without statistical significance ([Table 2](#t2-ijgm-7-411){ref-type="table"}).

After adjusting for propensity score (age, splenectomy, acetyl salicylic acid, NYHA class, clinical right heart failure, O~2~ saturation, baseline PASP, left ventricular ejection fraction, diastolic function, hemoglobin level, platelet count, nucleated red cell, baseline serum ferritin level, and baseline 6-minute walk distance) and right ventricular systolic function, after 12 months of treatment, Group 1 had a mean PASP reduction greater than that of Group 2 (adjusted mean difference, −16.83; 95% confidence interval \[CI\], −26.35 to −7.32; *P*=0.001). The mean 6-minute walk distance at 12 months in Group 1 was greater than that in Group 2 (adjusted mean difference, 46.55; 95% CI, 18.08 to 75.02; *P*=0.001; [Table 3](#t3-ijgm-7-411){ref-type="table"}). Chronic blood transfusions improved functional class status and clinical outcome of clinical right heart failure at 6 and 12 months after treatment. None of the patients had clinical evidence of thromboembolism (deep-vein thrombosis, pulmonary embolism, stroke). No patients were prematurely terminated from the study.

Discussion
==========

In the study reported here, chronic blood transfusions had a significant effect on PASP and mean 6-minute walk distance after 12 months. The results of this study support the treatment of thalassemic patients with PAH with chronic blood transfusions, according to a previous study that showed that correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusions was seen in an asplenic E/β-Thal patient.[@b18-ijgm-7-411]

A previous study showed that PAH is typical in TI patients who do not receive transfusions.[@b11-ijgm-7-411] PAH in thalassemia has also been associated with platelet activation and a hypercoagulable state.[@b4-ijgm-7-411] Diverse factors contributing to the hypercoagulable state in patients with thalassemia have been identified.[@b19-ijgm-7-411] Hypercoagulability is a well-described comorbid state in β-thalassemics who do not receive transfusions.[@b8-ijgm-7-411] Plasma heparin cofactor II levels were found to be significantly lower in TI patients who did not receive transfusions than in thalassemia major patients who received transfusions.[@b20-ijgm-7-411]

Management of PAH is symptomatic and supportive to improve right ventricular function. Acetyl salicylic acid[@b21-ijgm-7-411],[@b22-ijgm-7-411] and an anticoagulant[@b8-ijgm-7-411],[@b23-ijgm-7-411] are also prescribed by some. Response to treatment is poor and the survival of patients of NYHA functional class III to IV is about 1 to 2 years.

The marked reduction in PASP achieved in our study suggests an improvement in thrombotic pulmonary arteriopathy as a result of chronic blood transfusions.

The preference 14 patients had for occasional transfusions was due to the amount of time required to travel to and from hospital; consequently, they could not manage visiting more than once per month.

The present study may have some limitations as it was not a randomized controlled trial due to ethics considerations, but the propensity score adjustment was applied to cope with such limitations.

Conclusion
==========

The findings of the study presented here suggest that chronic blood transfusions might have beneficial effects on PAH in thalassemia patients over 1 year.
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###### 

Baseline characteristics of the patients[a](#tfn1-ijgm-7-411){ref-type="table-fn"}

  Characteristic                                                                      Chronic transfusion, n=16   Occasional transfusion, n=14   *P*-value
  ----------------------------------------------------------------------------------- --------------------------- ------------------------------ -----------
  Male (n \[%\])                                                                      4 (25.0)                    4 (28.6)                       1.000
  Age (years)                                                                         36.1±14.6                   34.1±15.2                      0.708
  Weight (kg)                                                                         40.1±8.4                    44.2±6.7                       0.165
  Height (cm)                                                                         149.8±7.5                   154.1±10.1                     0.196
  Splenectomy (n \[%\])                                                               8 (50.0)                    4 (28.6)                       0.284
  NYHA classification (n \[%\])                                                                                                                  
   II                                                                                 11 (68.7)                   14 (100.0)                     0.045
   III                                                                                5 (31.3)                    0                              0.045
  Clinical right heart failure[\*](#tfn2-ijgm-7-411){ref-type="table-fn"} (n \[%\])   5 (31.3)                    3 (21.4)                       0.689
  Acetyl salicylic acid (n \[%\])                                                     13 (81.2)                   11 (78.6)                      1.000
  Systolic blood pressure (mmHg)                                                      108.6±10.9                  112.9±14.4                     0.360
  Diastolic blood pressure (mmHg)                                                     64.4±7.8                    68.7±11.3                      0.235
  Pulse rate (/minute)                                                                82.5±12.8                   84.2±13.2                      0.721
  O~2~ saturation (%)                                                                 95.7±3.2                    96.6±4.0                       0.306
  Hemoglobin (g/dL)                                                                   6.6±1.0                     6.0±1.3                        0.149
  Corrected white blood cells (×10^3^/μL)                                             10.3±6.4                    8.5±4.4                        0.454
  Platelets (×10^3^/μL)                                                               413.5±275.5                 331.1±328.3                    0.270
  Nucleated RBC/100 WBC                                                               177.2±225.7                 188.1±308.8                    0.706
  PT (second)                                                                         13.8±2.8                    13.0±1.2                       0.818
  PTT (second)                                                                        31.8±2.2                    30.1±2.8                       0.072
  INR                                                                                 1.3±0.2                     1.2±0.1                        0.250
  Aspartate transaminase (IU/L)                                                       66.8±62.3                   41.7±24.9                      0.096
  Alanine transaminase (IU/L)                                                         36.1±27.5                   28.1±18.2                      0.441
  HBs Ag positive (n \[%\])                                                           1 (6.2)                     1 (7.1)                        1.000
  Anti-HCV positive (n \[%\])                                                         2 (12.5)                    0                              0.485
  Serum creatinine (mg/dL)                                                            0.8±0.2                     0.7±0.2                        0.208
  Serum ferritin (μg/L)                                                               1,592.8±868.1               1,378.6±649.9                  0.456
  **Echocardiographic finding**                                                                                                                  
  PASP (mmHg)                                                                         59.7±15.1                   49.0±13.8                      0.054
  PASP (mmHg) severity (n \[%\])                                                                                                                 
   36--50 mmHg (mild)                                                                 4 (25.0)                    10 (71.4)                      0.049
   51--70 mmHg (moderate)                                                             8 (50.0)                    2 (14.3)                       0.058
   \>70 mmHg (severe)                                                                 4 (25.0)                    2 (14.3)                       0.657
  LVEF (%)                                                                            62.8±8.5                    63.6±8.6                       0.807
  LVESd (mm)                                                                          9.8±2.5                     9.9±1.9                        0.888
  LVEDd (mm)                                                                          51.6±4.9                    52.0±5.6                       0.820
  MPAd (mm)                                                                           26.7±5.4                    25.7±4.4                       0.571
  RVd (mm)                                                                            32.1±10.1                   29.9±3.2                       0.441
  Poor right ventricular systolic function (n \[%\])                                  7 (43.7)                    2 (14.3)                       0.118
  Diastolic function                                                                                                                             
  Mitral valve E:A ratio                                                              1.4±0.5                     1.6±0.5                        0.337
  Mitral valve DT (ms)                                                                200.1±26.7                  201.1±6.8                      0.884
  Baseline 6-minute walk distance (m)                                                 357.5±88.5                  371.8±75.5                     0.640
  Propensity score                                                                    0.8±0.3                     0.2±0.2                        \<0.001

**Notes:**

Values shown are mean ± standard deviation unless otherwise specified.

Elevated jugular venous pressure, hepatojugular reflux, and edema.

**Abbreviations:** DT, deceleration time; E:A, ratio of the early (E) to late (A) ventricular filling velocities; HBs Ag, hepatitis B surface antigen; HCV, hepatitis C virus; INR, international normalized ratio; LVEDd, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LVESd, left ventricular end systolic diameter; MPAd, main pulmonary artery diameter; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; PT, prothrombin time; PTT, partial thromboplastin time; RBC, red blood cells; RVd, right ventricular diameter; WBC, white blood cells.

###### 

Comparison of clinical outcomes, echocardiographic findings, and 6-minute walk distance at 6 and 12 months[a](#tfn4-ijgm-7-411){ref-type="table-fn"}

  Outcome                                               Chronic transfusion, n=16   Occasional transfusion, n=14   *P*-value
  ----------------------------------------------------- --------------------------- ------------------------------ -----------
  Treatment: red cell transfusion (units/year)          23.9±8.1                    4.1±2.2                        \<0.001
  **6 months**                                                                                                     
  Hemoglobin (g/dL)                                     7.5±0.9                     6.2±1.3                        0.005
  Serum ferritin (μg/L)                                 1,920.9±795.8               1,635.6±817.7                  0.318
  Clinical                                                                                                         
   NYHA classification (n \[%\])                                                                                   
    II                                                  16 (100.0)                  12 (85.7)                      0.209
    III                                                 0                           2 (14.3)                       
   Clinical right heart failure (n \[%\])               1 (6.2)                     2 (14.3)                       0.586
   O~2~ saturation (%)                                  96.0±4.6                    96.3±4.0                       0.593
  Echocardiographic finding                                                                                        
   PASP (mmHg)                                          50.4±14.6                   49.4±16.9                      0.308
   LVEF (%)                                             62.2±9.7                    61.3±9.0                       0.933
   MPAd (mm)                                            27.2±5.2                    27.0±5.0                       0.842
   RVd (mm)                                             30.2±6.7                    30.4±3.9                       0.786
   Poor right ventricular systolic function (n \[%\])   2 (12.5)                    2 (14.3)                       1.000
   Diastolic function                                                                                              
   Mitral valve E:A ratio                               1.1±0.3                     1.4±0.6                        0.084
   Mitral valve DT (ms)                                 213.0±16.7                  215.3±33.7                     0.812
  6-minute walk distance (m)                            388.7±59.2                  368.6±61.1                     0.462
  **12 months**                                                                                                    
  Hemoglobin (g/dL)                                     7.2±1.1                     5.7±1.6                        0.006
  Serum ferritin (μg/L)                                 2,070.7±825.2               1,633.3±1,049.0                0.145
  Clinical                                                                                                         
   NYHA classification (n \[%\])                                                                                   
    II                                                  16 (100.0)                  13 (92.9)                      0.467
    III                                                 0                           1 (7.14)                       
   Clinical right heart failure (n \[%\])               0                           1 (7.14)                       0.467
   O~2~ saturation (%)                                  95.6±5.1                    96.3±3.0                       0.814
  Echocardiographic finding                                                                                        
   PASP (mmHg)                                          48.8±18.8                   54.1±21.4                      0.770
   LVEF (%)                                             66.0±7.9                    64.8±10.4                      0.868
   MPAd (mm)                                            26.7±4.1                    27.7±4.8                       0.557
   RVd (mm)                                             27.1±7.0                    30.0±4.7                       0.197
   Poor right ventricular systolic function (n \[%\])   2 (12.5)                    2 (14.3)                       1.000
   Diastolic function                                                                                              
   Mitral valve E:A ratio                               1.3±0.6                     1.5±0.7                        0.288
   Mitral valve DT (ms)                                 195.9±40.1                  202.8±11.6                     0.369
  6-minute walk distance (m)                            403.7±53.8                  350.0±82.9                     0.084

**Note:**

Values shown are mean ± standard deviation unless otherwise specified.

**Abbreviations:** DT, deceleration time; E:A, ratio of the early (E) to late (A) ventricular filling velocities; LVEDd, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; MPAd, main pulmonary artery diameter; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RVd, right ventricular diameter.

###### 

Effect of chronic blood transfusion on clinical outcomes, echocardiographic findings and 6-minute walk distance

  Outcome                                                                                   Adjusted effect[\*](#tfn6-ijgm-7-411){ref-type="table-fn"} (95% CI)   *P*-value
  ----------------------------------------------------------------------------------------- --------------------------------------------------------------------- -----------
  **6 months**                                                                                                                                                    
  Clinical                                                                                                                                                        
   NYHA class III (n)[a](#tfn7-ijgm-7-411){ref-type="table-fn"}                             −0.37 (−0.37 to −0.37)                                                \<0.001
   Clinical right heart failure (n)[a](#tfn7-ijgm-7-411){ref-type="table-fn"}               −0.37 (−0.37 to −0.37)                                                \<0.001
   O~2~ saturation (%)[b](#tfn8-ijgm-7-411){ref-type="table-fn"}                            −1.53 (−15.39 to 12.33)                                               0.829
  Echocardiographic finding                                                                                                                                       
   PASP (mmHg)[b](#tfn8-ijgm-7-411){ref-type="table-fn"}                                    −6.67 (−16.68 to 3.35)                                                0.192
   LVEF (%)[b](#tfn8-ijgm-7-411){ref-type="table-fn"}                                       4.70 (−6.63 to 16.04)                                                 0.416
   Poor right ventricular systolic function (n)[c](#tfn9-ijgm-7-411){ref-type="table-fn"}   0.51 (0.23 to 1.13)                                                   0.099
   Diastolic function                                                                                                                                             
   Mitral valve E:A ratio[b](#tfn8-ijgm-7-411){ref-type="table-fn"}                         −0.28 (−1.91 to 1.36)                                                 0.739
   Mitral valve DT (ms)[b](#tfn8-ijgm-7-411){ref-type="table-fn"}                           −31.68 (−50.99 to −12.38)                                             0.001
  6-minute walk distance (m)[b](#tfn8-ijgm-7-411){ref-type="table-fn"}                      10.88 (−17.45 to 39.22)                                               0.451
  **12 months**                                                                                                                                                   
  Clinical                                                                                                                                                        
   NYHA class III (n)[a](#tfn7-ijgm-7-411){ref-type="table-fn"}                             −0.14 (−0.15 to −0.14)                                                \<0.001
   Clinical right heart failure (n)[a](#tfn7-ijgm-7-411){ref-type="table-fn"}               −0.14 (−0.15 to −0.14)                                                \<0.001
   O~2~ saturation (%)[b](#tfn8-ijgm-7-411){ref-type="table-fn"}                            3.76 (−10.02 to 17.54)                                                0.593
  Echocardiographic finding                                                                                                                                       
   PASP (mmHg)[b](#tfn8-ijgm-7-411){ref-type="table-fn"}                                    −16.83 (−26.35 to −7.32)                                              0.001
   LVEF (%)[b](#tfn8-ijgm-7-411){ref-type="table-fn"}                                       3.02 (−8.90 to 14.94)                                                 0.619
   Poor right ventricular systolic function (n)[c](#tfn9-ijgm-7-411){ref-type="table-fn"}   0.51 (0.23 to 1.13)                                                   0.099
   Diastolic function                                                                                                                                             
   Mitral valve E:A ratio[b](#tfn8-ijgm-7-411){ref-type="table-fn"}                         0.28 (−1.39 to 1.95)                                                  0.744
   Mitral valve DT (ms)[b](#tfn8-ijgm-7-411){ref-type="table-fn"}                           −32.48 (−52.44 to −12.53)                                             0.001
  6-minute walk distance (m)[b](#tfn8-ijgm-7-411){ref-type="table-fn"}                      46.55 (18.08 to 75.02)                                                0.001

**Notes:**

Adjusted for propensity score (age, splenectomy, acetyl salicylic acid, NYHA classification, clinical right heart failure, O~2~ saturation, baseline pulmonary artery systolic pressure, left ventricular ejection fraction, diastolic function, hemoglobin level, platelet count, nucleated red cell, baseline serum ferritin level, and baseline 6-minute walk test) and right ventricular systolic function.

Generalized linear models: extensions to the binomial family: risk difference

generalized linear models: Poisson regression

generalized linear models: extensions to the binomial family: risk ratio.

**Abbreviations:** CI, confidence interval; DT, deceleration time; E:A, ratio of the early (E) to late (A) ventricular filling velocities; LVEF, left ventricular ejection fraction; MPAd, main pulmonary artery diameter; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RVd, right ventricular diameter.
